KDMN News and Press, Kadmon Holdings Inc. From 12/27/18

Kadmon Holdings (NYSE: KDMN ) Chairman Bart M. Schwartz steps down as director and chairman due to increasing responsibilities at his charitable commitments, including All Stars Project youth nonprofit and the Police Athletic League. More news on: Kadmon Holdings, Healthcare stocks news, ...

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Bart M. Schwartz, Esq. is stepping down as director and Chairman of the Board of Directors (the “Board”) due to increasing responsibilities at his charitable commitments, includ...

Kadmon Holdings (NYSE: KDMN ) is up  41%  premarket on light volume on the heels of updated results from a Phase 2 clinical trial evaluating KD025 in patients with previously treated chronic graft-versus-host disease (GvHD). The data were presented at ASH in San Diego. More n...

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), in patients with previously treated chronic graft-versus...

NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the presentation of preclinical data supporting the therapeutic potential of Rho-associated coiled-coil kinase (ROCK) inhibition for the treatment of fibrotic diseases. The data will be presented ...

NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kadmon Holdings, Inc. (NYSE:KDMN), Overstock.com, Inc. (NASDAQ:OSTK), AEC...

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 at 8:40 a.m. GMT (3:40 a.m. ET). A ...

NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking pla...

2018 YTD Chart: +56.48% New High YTD Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 45: The Momentum Gauges finally showed some improvement after deteriorating since week 39. The positive momentum gauge increased slightly to 18 this week from a ...

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that updated data from its ongoing Phase 2 clinical trial evaluating KD025 for the treatment of chronic graft-versus-host disease (cGVHD) have been selected for oral presentation at the 60 th Ame...